uploads/2018/09/Chart-005-1-1.jpg

Allergan’s SpotLyte and Lumivive System

By

Updated

Allergan’s announcements

On September 12, Allergan (AGN) announced the launch of SpotLyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. On September 6, Allergan announced the launch of its dual-acting product, the SkinMedica Lumivive System.

Article continues below advertisement

SpotLyte

SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics. SpotLyte is a digital hub designed to help consumers determine how medical aesthetic treatments may fit their routines. The site is designed with the goal of providing well-researched and accurate information.

The brand-agnostic site is designed to provide unbiased information to consumers. The site also has a chat feature that connects consumers with specialists for information about the treatments and local licensed providers.

Lumivive

The SkinMedica Lumivive System is a skincare product that is designed to work as a shield from blue light during the day and works as a skin repair product at night. According to the company, the Lumivive System offers atmospheric protection during the day and fights signs of aging.

Allergan noted that Lumivive is designed to work with the existing SkinMedica products such as HA5 Rejuvenating Hydrator, TNS Essential Serum, and Total Defense and Repair broad-spectrum sunscreens.

The Invesco Dynamic Pharmaceuticals ETF (PJP) holds 3.0% in Allergan (AGN), 5.6% in Eli Lilly & Co. (LLY), 4.9% in Gilead Sciences (GILD), and 2.9% in Biogen (BIIB).

Advertisement

More From Market Realist